Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KIORA PHARMACEUTICALS INCKPRX · Entity 7940 | Director · President and CEO | July 01, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KIORA PHARMACEUTICALS INC
Report date July 01, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,823 |
Reported balance
After 2026-07-01 transaction · row 1
1 source rowRow 1 · 2026-07-01 · Tax withholding · Disposed 1,869 · Balance 58,823 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 2, 2026 20:46 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | Tax withholdingCommon Stock | 1,869 | $2.66 | $4,971.54 |
DisclosureSEC source: 0001372514-26-000065 · wk-form4_1783025197.xml · nonDerivative · entry 1 Strem Brian M. · CIK 0001876429 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,823 Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 20:45 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | Tax withholdingCommon Stock | 1,906 | $1.95 | $3,716.70 |
DisclosureSEC source: 0001372514-26-000030 · wk-form4_1775162730.xml · nonDerivative · entry 1 Strem Brian M. · CIK 0001876429 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,692 Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:36 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 33,467 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001372514-26-000013 · wk-form4_1773175009.xml · derivative · entry 2 Strem Brian M. · CIK 0001876429 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,467 Underlying: Common Stock · 33,467 shares Expires 2036-04-01 F2 · derivative.exercise_date: The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on April 1, 2027, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:36 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantCommon Stock | 16,733 | $0.00 | $0.00 |
DisclosureSEC source: 0001372514-26-000013 · wk-form4_1773175009.xml · nonDerivative · entry 1 Strem Brian M. · CIK 0001876429 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,598 F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of April 1, 2027, April 1, 2028 and April 1, 2029, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| March 03, 2026 Filed Mar 6, 2026 19:03 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | Tax withholdingCommon Stock | 238 | $2.02 | $480.76 |
DisclosureSEC source: 0001372514-26-000006 · wk-form4_1772823806.xml · nonDerivative · entry 1 Strem Brian M. · CIK 0001876429 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,865 Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 00:28 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 31,883 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001372514-25-000034 · wk-form4_1743640097.xml · derivative · entry 2 Strem Brian M. · CIK 0001876429 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,883 Underlying: Common Stock · 31,883 shares Expires 2035-04-01 F2 · derivative.exercise_date: The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on April 1, 2026, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 00:28 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantCommon Stock | 15,941 | $0.00 | $0.00 |
DisclosureSEC source: 0001372514-25-000034 · wk-form4_1743640097.xml · nonDerivative · entry 1 Strem Brian M. · CIK 0001876429 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,103 F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of April 1, 2026, April 1, 2027 and April 1, 2028, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 19:16 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 31,259 | $0.00 Strike: $4.35 | $0.00 |
DisclosureSEC source: 0001372514-24-000097 · wk-form4_1720034205.xml · derivative · entry 2 Strem Brian M. · CIK 0001876429 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,259 Underlying: Common Stock · 31,259 shares Expires 2034-07-01 F2 · derivative.exercise_date: The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on July 1, 2025, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 19:16 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantCommon Stock | 15,629 | $0.00 | $0.00 |
DisclosureSEC source: 0001372514-24-000097 · wk-form4_1720034205.xml · nonDerivative · entry 1 Strem Brian M. · CIK 0001876429 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,160 F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of July 1, 2025, July 1, 2026 and July 1, 2027, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| June 13, 2024 Filed Jun 13, 2024 19:49 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | PurchaseCommon Stock | 3,000 | $5.00 | $14,997.00 |
DisclosureSEC source: 0001372514-24-000060 · wk-form4_1718308174.xml · nonDerivative · entry 1 Strem Brian M. · CIK 0001876429 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,531 Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 20:47 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001372514-23-000148 · wk-form4_1696366025.xml · derivative · entry 2 Strem Brian M. · CIK 0001876429 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-09-29 F2 · derivative.exercise_date: The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to twenty-five percent (25%) of the shares underlying the Option upon grant on September 29, 2023, twenty-five percent (25%) on September 29, 2024 and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 20:47 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001372514-23-000148 · wk-form4_1696366025.xml · nonDerivative · entry 1 Strem Brian M. · CIK 0001876429 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,783 F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan (the "Plan"). The restrictions will vest as to twenty-five percent (25%) of the shares immediately upon grant, and twenty-five percent (25%) on each of September 29, 2024, September 29, 2025 and September 29, 2026, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| March 03, 2023 Filed Mar 8, 2023 01:15 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 10,400 | $0.00 Strike: $3.83 | $0.00 |
DisclosureSEC source: 0001372514-23-000035 · wf-form4_167823809348747.xml · derivative · entry 2 Strem Brian M. · CIK 0001876429 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,400 Underlying: Common Stock · 10,400 shares Expires 2033-03-03 F2 · derivative.exercise_date: The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on March 3, 2024, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| March 03, 2023 Filed Mar 8, 2023 01:15 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantCommon Stock | 15,600 | $3.83 | $59,748.00 |
DisclosureSEC source: 0001372514-23-000035 · wf-form4_167823809348747.xml · nonDerivative · entry 1 Strem Brian M. · CIK 0001876429 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,783 F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of March 3, 2024, March 3, 2025 and March 3, 2026, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| October 21, 2022 Filed Oct 25, 2022 21:30 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $6.78 | $0.00 |
DisclosureSEC source: 0001104659-22-111239 · tm2228925-1_4seq1.xml · derivative · entry 2 Strem Brian M. · CIK 0001876429 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2032-10-21 F2 · derivative.exercise_date: The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on October 21, 2023, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| October 21, 2022 Filed Oct 25, 2022 21:30 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-111239 · tm2228925-1_4seq1.xml · nonDerivative · entry 1 Strem Brian M. · CIK 0001876429 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,183 F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of October 21, 2023, October 21, 2024 and October 21, 2025, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:01 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001104659-22-011491 · tm225348d2_4.xml · derivative · entry 1 Strem Brian M. · CIK 0001876429 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2023, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 21:35 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | PurchaseCommon Stock | 17,853 | $1.41 | $25,172.73 |
DisclosureSEC source: 0001104659-21-142537 · tm2133588-1_4seq1.xml · nonDerivative · entry 2 Strem Brian M. · CIK 0001876429 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,370 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.395 to $1.41, inclusive. The reporting person hereby undertakes to provide to Kiora Pharmaceuticals, Inc., any security holder of Kiora Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| October 21, 2021 Filed Nov 22, 2021 21:35 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantCommon Stock | 9,517 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-142537 · tm2133588-1_4seq1.xml · nonDerivative · entry 1 Strem Brian M. · CIK 0001876429 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,517 F1 · price: Received by the Reporting Person in connection with the acquisition by the issuer of all of the outstanding securities of Bayon Therapeutics, Inc. on October 21, 2021. Read SEC document |
| July 26, 2021 Filed Aug 2, 2021 21:30 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.12 | $0.00 |
DisclosureSEC source: 0001104659-21-098991 · tm2123223d1_4.xml · derivative · entry 1 Strem Brian M. · CIK 0001876429 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-07-26 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on July 26, 2022, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.